AGP Wins Silver Award at the SAFA Best Presented Annual Report Awards 2024

AGP Wins 1st Position in Pharmaceutical Category at BCSR Awards 2024 — for the Second Consecutive Year!

AGP Celebrates Dual Recognition at the 8th Pakistan Pharma Summit & PESA Awards 2025

AGP Receives the 22nd Annual Environment Excellence Award 2025

AGP Wins GDEIB Awards in Nine Categories

AGP x TrashIt Sustainability Training

AGP x Cyber Security Awareness Training

AGP x Cancer Foundation Hospital: Breast Cancer Awareness Session

AGP Visits Karachi Down Syndrome Program (KDSP)

Diwali Celebration at AGP: Honoring Diversity, Culture & Togetherness

AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Product List

Febuxin

Generic:

Febuxostat

 

Therapeutic Class:

Anti-Gout

 

Composition:

Each Febuxin tablet contains 40 or
80 mg of febuxostat for oral administration.

 

Description:

Febuxin (febuxostat) is a xanthine
oxidase inhibitor.

 

Indications:

Febuxin is indicated for the
chronic management of hyperuricemia in patients with gout.

 

Dosage:

For treatment of hyperuricemia in
patients with gout, Febuxin is recommended at 40 mg or 80 mg once daily. It
can be taken without regard to food or antacid use.

The recommended starting dose of Febuxin is 40 mg once daily. For patients
who do not achieve a serum uric acid (sUA) less than 6 mg per dL after 2
weeks with 40 mg, FEBUXIN 80 mg is recommended.

 

Presentations:

Febuxin tab 40 mg and 80 mg is available in blister pack of 20’s.